国际皮肤性病学杂志    2004 30 (1): 10-12   ISSN: 2096-5540  CN: 32-1880/R   卡泊芬净——一种新作用机制的抗真菌药 李玲珺, 马鹏程 中国医学科学院、中国协和医科大学皮肤病研究所 南京 210042 收稿日期 2003-05-21  修回日期 null  网络版发布日期 null 参考文献  [1] Abruzzo GK,Gill CJ,Flattery AM,et al.Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.Antimicrob Agents Chemother,2000,44(9):2310-2318. [2] Stone EA,Fung HB,Kirschenbaum HL.Caspofungin:an echinocandin antifungal agent.Clin Ther,2002,24(3):351-377. [3] Onishi J,Meinz M,Thompson J,et al.Discovery of novel antifungal(1,3)-beta-D-glucan synthase inhibitors.Antimicrob Agents Chemother,2000,44(2):368-377. [4] Vicente MF,Basilio A,Cabello A,et al.Microbial natural products as a source of antifungals.Clin Microbiol Infect,2003,9(1):15-32. [5] Del Poeta M,Cruz MC,Cardenas ME,et al.Synergistic antifungal activities of bafilomycin A(1),fluconazole,and the pneumocandin MK-0991/caspofungin acetate(L-743,873)with calcineurin in-hibitors FKS06 and L-685,818 against Cryptococcus neoformans.Antimicrob Agents Chemother,2000,44(3):739-746. [6] Bartizal K,Gill C J,Abruzzo GK,et al.In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991(L-743,872).Antimicrob Agents Chemother,1997,41(11):2326-2332. [7] Graybill JR,Najvar LK,Montalbo EM,et al.Treatment of histoplasmosis with MK-991(L-743,872).Antimicrob Agents Chemother,1998,42(1):151-153. [8] Del Poeta M,Schell WA,Perfect JR.In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.Antimicrob Agents Chemother,1997,41(8):1835-1836. [9] Vazquez JA,Lynch M,Boikov D,et al.In vitro activity of a new pneumocandin antifungal,L-743,872,against azole-susceptible and-resistant Candida species.Antimicrob Agents Chemother,1997,41(7):1612-1614. [10] PoMes MA,Liberator P,Anderson J,et al.Efficacy of MK-991(L-743,872),a semisynthetic pneumocandin,in murine models of Pneumocystis carinii.Antimicrob Agents Chemother,1998,42(8):1985-1989. [11] Pacetti SA,Gelone SP.Caspofungin acetate for treatment of invasive fungal infections.Ann Pharmacother,2003,37(1):90-98. [12] Espinel-Ingroff A.Evaluation of broth microdilution testing parametersand agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp.to caspofungin acetate(MK-0991).J Clin Microbiol,2003,41(1):403-409. [13] Arikan S,Lozano-Chiu M,Paetznick V,et al.In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.Antimicrob Agents Chemother,2001,45(1):327-330. [14] Hajdu R,Thompson R,Sundelof JG,et al.Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991(L-743,872).Antimicrob Agents Chemother,1997,41(11):2339-2344. [15] Hoang A.Caspofungin acetate:an antifungal agent.Am J Health Syst Pharm,2001,58(13):1206-1214. [16] Balani SK,Xu X,Arison BH,et al.Metabolites of easpofungin acetate,a potent antifungal agent,in human plasma and urine.Drug Metab Dispos,2000,28(11):1274-1278. [17] Abruzzo GK,Flattery AM,Gill CJ,et al.Evaluation of the echinocandin antifungal MK-0991(L-743,872):efficacies in mouse models of disseminated aspergillosis,eandidiasis,and cryptoeoccosis.Antimicrob Agents Chemother,1997,41(11):2333-2338. [18] Perea S,Patterson TF.Invasive Aspergillus infections in hematologic malignancy patients.Semin Respir Infect,2002,17(2):99-105. [19] Arathoon EG,Gotuzzo E,Noriega LM,et al.Randomized,doubleblind,multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.Antimicrob Agents Chemother,2002,46(2):451-457. 通讯作者: